Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Array Biopharma Inc (ARRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,158,579
  • Shares Outstanding, K 218,214
  • Annual Sales, $ 173,770 K
  • Annual Income, $ -147,350 K
  • 60-Month Beta 1.48
  • Price/Sales 30.20
  • Price/Cash Flow N/A
  • Price/Book 18.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.21
  • Number of Estimates 8
  • High Estimate -0.14
  • Low Estimate -0.30
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -90.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.37 +11.09%
on 03/08/19
24.56 -3.34%
on 03/14/19
+0.61 (+2.64%)
since 02/15/19
3-Month
13.06 +81.78%
on 12/24/18
24.56 -3.34%
on 03/14/19
+8.61 (+56.91%)
since 12/18/18
52-Week
12.56 +89.01%
on 10/11/18
24.56 -3.34%
on 03/14/19
+6.91 (+41.06%)
since 03/16/18

Most Recent Stories

More News
Uptrend Call Working As Array Biopharma Stock Rises 37.4% (ARRY)

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on January 7th, 2019 at $17.03. In approximately 2 months, Array Biopharma has returned 37.44% as of today's recent price of $23.40.

ARRY : 23.74 (+0.42%)
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer

Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network® (NCCN®) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include...

ARRY : 23.74 (+0.42%)
Watch for Array Biopharma to Potentially Pullback After Gaining 2.37% Yesterday

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $22.74 to a high of $23.28. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of...

ARRY : 23.74 (+0.42%)
Array Biopharma Up 28.2% Since SmarTrend Uptrend Call (ARRY)

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on January 7th, 2019 at $17.03. In approximately 2 months, Array Biopharma has returned 28.16% as of today's recent price of $21.82.

ARRY : 23.74 (+0.42%)
SmarTrend Watching for Potential Rebound in Shares of Array Biopharma After 2.50% Loss

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $22.47 to a high of $23.07. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $22.93...

ARRY : 23.74 (+0.42%)
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 39th Annual Cowen Health Care Conference in Boston. The public is welcome to participate...

ARRY : 23.74 (+0.42%)
Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Array BioPharma Inc. (NASDAQ:ARRY),...

FSP : 7.30 (-0.68%)
OZM : 16.23 (+2.08%)
ARRY : 23.74 (+0.42%)
PDM : 20.46 (-0.15%)
EAT : 44.15 (+0.94%)
NBR : 3.54 (+7.93%)
Array Biopharma Set to Possibly Pullback After Yesterday's Rally of 3.79%

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $23.02 to a high of $23.57. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of...

ARRY : 23.74 (+0.42%)
Array Biopharma Has Returned 33.4% Since SmarTrend Recommendation (ARRY)

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on January 7th, 2019 at $17.03. In approximately 2 month, Array Biopharma has returned 33.39% as of today's recent price of $22.71.

ARRY : 23.74 (+0.42%)
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York. The public...

ARRY : 23.74 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARRY with:

Business Summary

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory...

See More

Key Turning Points

2nd Resistance Point 24.18
1st Resistance Point 23.96
Last Price 23.74
1st Support Level 23.40
2nd Support Level 23.06

See More

52-Week High 24.56
Last Price 23.74
Fibonacci 61.8% 19.98
Fibonacci 50% 18.56
Fibonacci 38.2% 17.14
52-Week Low 12.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar